BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

994 related articles for article (PubMed ID: 18790133)

  • 1. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
    Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
    Dillon R; Greig MJ; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-throughput scintillation proximity assay for stearoyl-CoA desaturase-1.
    Tawa P; Falgueyret JP; Guiral S; Isabel E; Powell DA; Zuck P; Skorey K
    J Biomol Screen; 2011 Jun; 16(5):506-17. PubMed ID: 21406617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.
    Koltun DO; Parkhill EQ; Vasilevich NI; Glushkov AI; Zilbershtein TM; Ivanov AV; Cole AG; Henderson I; Zautke NA; Brunn SA; Mollova N; Leung K; Chisholm JW; Zablocki J
    Bioorg Med Chem Lett; 2009 Apr; 19(7):2048-52. PubMed ID: 19249203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
    Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
    Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of stearoyl-CoA desaturase activity by the trans-10,cis-12 isomer of conjugated linoleic acid in HepG2 cells.
    Choi Y; Park Y; Pariza MW; Ntambi JM
    Biochem Biophys Res Commun; 2001 Jun; 284(3):689-93. PubMed ID: 11396956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
    Dobrzyn A; Ntambi JM
    Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1-(4-phenoxypiperidin-1-yl)-2-arylaminoethanone stearoyl-CoA desaturase 1 inhibitors.
    Zhao H; Serby MD; Smith HT; Cao N; Suhar TS; Surowy TK; Camp HS; Collins CA; Sham HL; Liu G
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3388-91. PubMed ID: 17434733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stearoyl-CoA desaturase inhibitors: update on patented compounds.
    Liu G
    Expert Opin Ther Pat; 2009 Sep; 19(9):1169-91. PubMed ID: 19691439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).
    Léger S; Black WC; Deschenes D; Dolman S; Falgueyret JP; Gagnon M; Guiral S; Huang Z; Guay J; Leblanc Y; Li CS; Massé F; Oballa R; Zhang L
    Bioorg Med Chem Lett; 2010 Jan; 20(2):499-502. PubMed ID: 20004097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desaturation of myristoyl-CoA to myristoleoyl-CoA by hen liver microsomal delta(9)-desaturase.
    Awad AC; Shin HS; Romsos DR; Gray JI
    J Agric Food Chem; 2004 Jun; 52(13):4234-9. PubMed ID: 15212474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1'-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4'-piperidine] analogs.
    Uto Y; Ueno Y; Kiyotsuka Y; Miyazawa Y; Kurata H; Ogata T; Yamada M; Deguchi T; Konishi M; Takagi T; Wakimoto S; Ohsumi J
    Eur J Med Chem; 2010 Nov; 45(11):4788-96. PubMed ID: 20801551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
    Koltun DO; Vasilevich NI; Parkhill EQ; Glushkov AI; Zilbershtein TM; Mayboroda EI; Boze MA; Cole AG; Henderson I; Zautke NA; Brunn SA; Chu N; Hao J; Mollova N; Leung K; Chisholm JW; Zablocki J
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3050-3. PubMed ID: 19394219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Purification and characterization of Linoleoyl-CoA desaturase from rat liver microsomes (author's transl)].
    Okayasu T
    Hokkaido Igaku Zasshi; 1981 Jan; 56(1):43-54. PubMed ID: 7262818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of stearoyl-CoA desaturase in body weight regulation.
    Dobrzyn A; Ntambi JM
    Trends Cardiovasc Med; 2004 Feb; 14(2):77-81. PubMed ID: 15030794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.
    Atkinson KA; Beretta EE; Brown JA; Castrodad M; Chen Y; Cosgrove JM; Du P; Litchfield J; Makowski M; Martin K; McLellan TJ; Neagu C; Perry DA; Piotrowski DW; Steppan CM; Trilles R
    Bioorg Med Chem Lett; 2011 Mar; 21(6):1621-5. PubMed ID: 21324691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
    Dobrzyn P; Dobrzyn A
    Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
    Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
    J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological activity and preclinical efficacy of azetidinyl pyridazines as potent systemically-distributed stearoyl-CoA desaturase inhibitors.
    Isabel E; Powell DA; Black WC; Chan CC; Crane S; Gordon R; Guay J; Guiral S; Huang Z; Robichaud J; Skorey K; Tawa P; Xu L; Zhang L; Oballa R
    Bioorg Med Chem Lett; 2011 Jan; 21(1):479-83. PubMed ID: 21074991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
    Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
    Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.